Owlstone Medical Secures Major Funding for Innovations
Owlstone Medical, a frontrunner in the field of Breath Biopsy for early disease detection and precision medicine, has successfully closed a $27 million round of Series E financing. This significant investment is aimed at bolstering the development and commercialization of groundbreaking diagnostic solutions. Leading investors in this funding round include Ventura Capital, alongside contributions from Aviva Ventures, Horizons Ventures, and others. The Gates Foundation also joined in supporting this venture.
Investment for Growth and Development
The funds raised will play a crucial role in advancing Owlstone's proprietary Breath Biopsy platform. This revolutionary technology is designed to facilitate the creation of innovative diagnostic tests and point-of-care devices aimed at diagnosing health conditions non-invasively.
Early Detection of Lung Cancer
Among the critical areas of focus is the ongoing clinical trials for a screening test dedicated to the early detection of lung cancer, the leading cause of cancer-related deaths globally. Every year, lung cancer accounts for approximately 1.8 million fatalities, underscoring the urgent need for effective screening tools.
Expansion of the LIBRA Test
Further developments will also include the launch of the LIBRA test, a diagnostic tool for chronic liver diseases. This condition currently leads to over 2 million deaths annually, highlighting the necessity of early detection methods in healthcare.
Advancing Digestive Disease Diagnosis
Additionally, the company will commercialize the OMED Health Breath Analyzer, a cost-effective and portable device aimed at diagnosing and monitoring various digestive diseases. It is estimated that these conditions impact approximately 1 billion individuals worldwide, marking a significant area of need in healthcare diagnostics.
Vision and Validation from Industry Leaders
Mo El Husseiny, Founder and Managing Partner at Ventura Capital, emphasized the promising potential of breath-based diagnostics, citing Owlstone's significant partnerships with organizations like the U.S. Department of Defense and the FDA. These collaborations validate Owlstone's innovative approach and their commitment to making strides in early disease detection.
Commitment to Healthcare Innovation
Tom Grant, Head of Venture Investments at Aviva Investors, expressed confidence in Owlstone's advancements since their previous fundraising efforts. He noted the progress achieved through their innovative VOC Atlas database and diagnostic solutions targeting high-need clinical areas, which are now making their way to market.
Future of Breath Biopsy
Billy Boyle, co-founder and CEO of Owlstone Medical, highlighted the unwavering support they receive from their investors. He stated that this recent funding will enable the company to further its clinical trials and expedite the rollout of their unique breath tests in the market.
Frequently Asked Questions
What is Breath Biopsy?
Breath Biopsy is a non-invasive diagnostic technology that analyzes exhaled breath for biomarkers indicating various health conditions, enabling early disease detection.
How will Owlstone Medical use the $27 million raised?
The funds will be utilized for the development and commercialization of new diagnostic tests and devices, including ongoing clinical trials for lung cancer detection.
Who are the key investors in the Series E round?
The Series E financing round was led by Ventura Capital with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation.
What health problems are targeted with the LIBRA test?
The LIBRA test is aimed at the early diagnosis of chronic liver diseases, which lead to significant mortality rates worldwide.
How does the OMED Health Breath Analyzer work?
The OMED Health Breath Analyzer is a hand-held device that tests breath samples to diagnose and monitor digestive diseases, providing a cost-effective and portable solution for healthcare providers.
